Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b|2 ELEVATE and ELECTRA Combination Studies of ORSERDU(r) (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Source :: Plus Company Updates. December 12, 2023
Publication Year :: 2023
Abstract: FLORENCE: Menarini Industrie Farmaceutiche Riunite has issued the following news release: The Menarini Group ('Menarini'), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ('Stemline'), a wholly-owned subsidiary [...]

Subjects :: Stemline Therapeutics Inc. -- Conferences, meetings and seminars
Medical research -- Conferences, meetings and seminars
Medicine, Experimental -- Conferences, meetings and seminars
Cancer patients -- Conferences, meetings and seminars -- Drug therapy
Metastasis -- Conferences, meetings and seminars -- Drug therapy
Antineoplastic agents -- Conferences, meetings and seminars
Conferences and conventions -- Conferences, meetings and seminars
Clinical trials -- Conferences, meetings and seminars
Breast cancer -- Conferences, meetings and seminars -- Drug therapy
Pharmaceutical industry -- Conferences, meetings and seminars
Antimitotic agents -- Conferences, meetings and seminars
General interest
News, opinion and commentary
Orserdu (Medication)

Tools